Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.

导出 OA

翻译打印收藏纠错

作者： Giovanni,Castelnovo ^[1] ; Oliver,Gerlach ^[2] ; Mark S,Freedman ^[3] ; Arnfin,Bergmann ^[4] ; Vladimiro,Sinay ^[5] ; Tamara,Castillo-Triviño ^[6] ; George,Kong ^[7] ; Thijs,Koster ^[8] ; Heather,Williams ^[9] ; Arie R,Gafson ^[10] ; Joep,Killestein ^[8]

作者单位： Service de Neurologie, CHU Caremeau, Nimes, France. ^[1] Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands. ^[2] Academic MS Center Limburg, School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands. ^[3] Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. ^[4] NeuroTransData GmbH, Neuburg an der Donau, Germany. ^[5] Institute of Translational and Cognitive Neuroscience (INCyT) INECO Foundation, Favaloro University, Buenos Aires, Argentina. ^[6] Donostia University Hospital, San Sebastian, Spain. ^[7] Biogen, Cambridge, MA, USA. ^[8] Biogen, Cambridge, MA, USA. thijs.koster@biogen.com. ^[9] Biogen, Maidenhead, Berkshire, UK. ^[10] Department of Neurology, MS Center Amsterdam, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands. ^[11]